9th International Endocrinology Conference 2026 | BESCON 2026

During the event, I focused my discussions on two critical areas of modern clinical practice:

Evaluating the efficacy, potential, and scientific limitations of Myoinositol in treating Polycystic Ovary Syndrome (PCOS) and PMOS is a highly timely discussion. It is essential to weigh the safety and effectiveness of these novel therapeutic approaches against conventional treatments, relying strictly on robust clinical evidence to guide patient care.

Modern osteoporosis management requires moving beyond relying solely on Bone Mineral Density (BMD). Comprehensive fracture risk assessment, personalized medicine, and risk-based therapy selection are paramount. This targeted approach ensures that high-risk patients receive timely interventions, providing long-term protection for their bone health.

Both topics represent fundamental priorities in clinical endocrinology, reinforcing the absolute necessity of evidence-based medicine and patient-centered care.

Conference Details:

Date: November 5–6, 2026

Venue: Pan Pacific Sonargaon, Dhaka

BESCON 2026 served as an invaluable platform for exchanging scientific knowledge, sharing clinical experiences, and continuously elevating the standard of care we provide to our patients.